Symposium: Update on prediction and management of OHSS: Prevention of OHSS - Dopamine agonists

Reproductive BioMedicine Online

Volumn 19, Issue 1, 2009, Pages 43-51

  Busso, Cristiano E ^a   Garcia Velasco, Juan ^a   Gomez, Raúl ^a   Álvarez, Claudio ^b   Simón, Carlos ^a,c   Pellicer, Antonio ^a,d  

^a INSTITUTO VALENCIANO DE INFERTILIDAD   (Spain)

^b Instituto Valenciano de Infertlidad Santiago de Chile   (Chile)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Assisted reproductive technologies; Dopamine agonists; Ovarian hyperstimulation syndrome; Vascular endothelial growth factor

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CD31 ANTIGEN; CHORIONIC GONADOTROPIN; DOCARPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PLACEBO; PROLACTIN; QUINAGOLIDE; SEMAXANIB; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ASCITES FLUID; BLOOD VESSEL PERMEABILITY; CONFERENCE PAPER; DISEASE SEVERITY; DOPAMINE METABOLISM; DRUG PENETRATION; DRUG SAFETY; FERTILIZATION IN VITRO; FLUID SHIFT; HEMOCONCENTRATION; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEAL PHASE; NONHUMAN; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY RATE; PROPHYLAXIS; PROTEIN PHOSPHORYLATION; TREATMENT DURATION;

EID: 68149099705     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60044-2     Document Type: Conference Paper

References (78)

1. Aboulghar MA, Mansour RT, Serour GI et al. 1998 Elevated levels of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Human Reproduction 13, 2068-2071. (Pubitemid 28425088)
2. Abramov Y, Elchalal U, Schenker JG 1999 Severe OHSS: An 'epidemic' of severe OHSS: a price we have to pay? Human Reproduction 14, 2181-2183.
3. Abramov Y, Barac V, Nisman B et al. 1997 Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertility and Sterility 67, 261-265. (Pubitemid 27052182)
4. Agrawal R, Tan SL, Wild S et al. 1999 Serum vascular endothelial growth factor concentrations in in-vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertility and Sterility 71, 287-293. (Pubitemid 29069906)
5. Albert C, Garrido N, Rao CV et al. 2002 The role of the endothelium in the pathogenesis of ovarian hyperstimulation syndrome. Molecular Human Reproduction 8, 409-418. (Pubitemid 34567918)
6. Álvarez C, Martí-Bonmatí L, Novella-Maestre E et al. 2007a Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism 92, 2931-2937. (Pubitemid 47236352)
7. Alvarez C, Alonso-Muriel I, Garcia G et al. 2007b Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Human Reproduction 22, 3210-3214. (Pubitemid 351696781)
8. Antczak M, Van Blerkom J 2000 The vascular character of ovarian follicular granulosa cells: phenotypic and functional evidence for an endothelial-like cell population. Human Reproduction 15, 2306-2318. (Pubitemid 30827183)
9. Basu S, Nagy J, Pal S et al. 2001 The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor. Nature Medicine 7, 569-574. (Pubitemid 32448324)
10. Bergh PA, Navot D 1992 Ovarian hyperstimulation syndrome: a review of pathophysiology. Journal of Assisted Reproduction and Genetics 9, 429-1138
11. Brekken RA, Overholser JP, Stastny VA et al. 2000 Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Research 60, 5117-5124.
12. Burchardt M, Burchardt T, Chen MW et al. 1999 Expression of messenger ribonucleic acid splice variants for the vascular endothelial growth factor in the penis of adult rats and humans. Biology of Reproduction 60, 398-404. (Pubitemid 29063882)
13. Busso C, Fernández-Sánchez M, García-Velasco JA et al. 2008 Quinagolide is effective in preventing moderate/severe early OHSS in IFV patients: a randomized, double-blind, placebo controlled trial. Human Reproduction 23 (Suppl. 1), i60.
14. Chen CD, Wu MY, Chen HF et al. 1999 Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertility and Sterility 72, 286-292.
15. Christin-Maitre S, Rongiéres-Bertrand C, Kottler ML et al. 1998 A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. Journal of Clinical Endocrinology and Metabolism 83, 3450-3453.
16. De Vries C, Escobedo JA, Ueno H et al. 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
17. Delbaere A, Smits G, Olatunbosun O et al. 2004 New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Human Reproduction 19, 486-489.
18. Enskog A, Henriksson M, Unander M et al. 1999 Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in-vitro fertilization. Fertility and Sterility 71, 808-814. (Pubitemid 29206902)
19. Ferraretti A P, Gianaroli L, Diotallevi L et al. 1992 Dopamine treatment for severe ovarian hyperstimulation syndrome. Human Reproduction 7, 180-183.
20. Fulghesu AM, Villa P, Pavone V et al. 1997 The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82, 644-648. (Pubitemid 27068644)
21. Glade-Bender J, Kandel JJ, Yamashiro DJ 2003 VEGF blocking therapy in the treatment of cancer. Expert Opinion Biology Therapy 3, 263-276. (Pubitemid 36458758)
22. Goldsman MP, Pedram A, Dominguez CE et al. 1995 Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertility and Sterility 63, 268-272.
23. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC et al. 2006 Low- dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147, 5400-5411. (Pubitemid 44790595)
24. Gómez R, Simón C, Remohi J et al. 2003 Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biology of Reproduction 68, 2164-2671. (Pubitemid 36687009)
25. Gómez R, Simón C, Remohi J et al. 2002 Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143, 4339-4348. (Pubitemid 35239566)
26. Gordon JD, Mesiano S, Zaloudek CJ et al. 1996 Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. Journal of Clinical Endocrinology and Metabolism 81,353-359. (Pubitemid 26035045)
27. Hornig C, Behn T, Bartsch W et al. 1999 Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. Journal of Immunological Methods 226,169-177. (Pubitemid 29336541)
28. Kendall RL, Thomas KA 1993 Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of America 90, 10705-10709. (Pubitemid 23347111)
29. Kendall RL, Wang G, Thomas KA 1996 Identification of a natural soluble form of the vascular endothelial growth factor receptor, Ht-1, and its heterodimerization with KDR. Biochemical and Biophysical Research Communications 226, 324-328.
30. Knoepfelmacher M, Danilovic DL, Rosa Nasser RH et al. 2006 Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertility and Sterility 86, 719. (Pubitemid 44316816)
31. Knox GE 1974 Antihistamine blockade of the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology 118, 992-994.
32. Kobayashi H, Okada Y, Asahina J et al. 1998 The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased VP associated with ovarian hyperstimulation syndrome. Journal of Molecular Endocrinology 20, 363-374. (Pubitemid 28277525)
33. Kuenen BC, Tabernero J, Baselga J et al. 2003 Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clinical Cancer Research 9,1648-1655. (Pubitemid 36554587)
34. Loret de Mola JR, Baumgardner GP, Goldfarb JE et al. 1996 Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumor necrosis factor-alpha cannot predict its occurrence. Human Reproduction 7, 1377-1380.
35. Magini A, Granchi S, Orlando C etal. 1996 Expression of endothelin-1 gene and protein in human granulosa cells. Journal of Clinical Endocrinology and Metabolism 81, 1428-1433.
36. Manno M, Tomei F, Marchesan E et al. 2005 Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? European Journal of Obstetrics, Gynecology, and Reproductive Biology 122, 127-128.
37. Marx GM, Steer CB, Harper P et al. 2002 Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! Journal of Clinical Oncology 20, 1446-1448.
38. McClure N, Healy DL, Rogers PA et al. 1994 Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome. Lancet 344, 235-236. (Pubitemid 24229013)
39. Murata Y, Ando H, Nagasaka T, Takahashi I et al. 2003 Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. Journal of Clinical Endocrinology and Metabolism 88, 1988-1993.
40. Navot D, Bergh PA, Laufer N 1992 Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 58, 249-261.
41. Navot D, Margalioth EJ, Laufer N 1987 Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertility and Sterility 48, 57-61. (Pubitemid 17093253)
42. Neufeld G, Cohen T, Gengrinovitch S et al. 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 13, 9-22. (Pubitemid 29038270)
43. Neulen J, Yan Z, Raczek S, Raczek S et al. 1995 Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. Journal of Clinical Endocrinology and Metabolism 80, 1967-1971.
44. Olson TA, Mohanraj D, Carson LF et al. 1994 VP factor gene expression in normal and neoplastic human ovaries. Cancer Research 54, 276-280.
45. Otani N, Minami S, Yamoto M et al. 1999 The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. The Journal of Clinical Endocrinology and Metabolism 84, 3845-3851. (Pubitemid 30645251)
46. Papaleo E, Doldi N, De Santis L et al. 2001 Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Human Reproduction 16, 2263-2266. (Pubitemid 33054119)
47. Pau E, Alonso-Muriel I, Gomez R et al. 2006 Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Human Reproduction 21, 1453-1460. (Pubitemid 44445021)
48. Pellicer A, Albert C, Mercader A et al. 1999 The pathogenesis of ovarian hyperstimulation syndrome: in-vivo studies investigating the role of interleukin-lbeta, interleukin-6, and vascular endothelial growth factor. Fertility and Sterility 71, 482-489. (Pubitemid 29094125)
49. Phillips HS, Hains J, Leung DW et al. 1990 Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965-967. (Pubitemid 20248145)
50. Quinn TP, Peters KG, De Vries C et al. 1993 Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America 90, 7533-7537. (Pubitemid 23249984)
51. Rizk B, Aboulghar M 1991 Modern management of ovarian hyperstimulation syndrome. Human Reproduction 6, 1082-1087.
52. Rizk B, Aboulghar M, Smitz J et al. 1997 The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update 3, 255-266. (Pubitemid 27437930)
53. Roberts WG, Palade GE 1995 Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cell Science 108, 2369-2379.
54. Roeckle W, Hecht D, Sztajer H et al. 1998 Differential binding characteristics and cellular inhibition by soluble VEGF receptor 1 and 2. Experimental Cell Research 241, 161-170. (Pubitemid 28366590)
55. Sarkar C, Chakroborty D, Mitra RB 2004 Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. American Journal of Physiology, Heart and Circulatory Physiology 287, H1554-H1560. (Pubitemid 39313259)
56. Schenker JG, Weinstein D 1978 Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility 30, 255-268. (Pubitemid 8397513)
57. Senger DR, Van De Water L, Brown LF et al. 1993 Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Reviews 12, 303-324. (Pubitemid 23293287)
58. Senger DR, Connolly DT, Van De Water L et al. 1990 Purification and NH2-terminal amino acid sequence of guinea pig tumor secreted vascular permeability factor. Cancer Research 50, 1774-1778. (Pubitemid 20098819)
59. Senger DR, Galli SJ, Dvorak E et al. 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
60. Shalaby F, Rossant J, Yamaguchi TP et al. 1995 Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
61. Shima DT, Kuroki M, Deutsch U et al. 1996 The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. Journal of Biological Chemistry 271, 3877-3883. (Pubitemid 26065709)
62. Shimon I, Rubenek T, Bar-Hava I et al. 2001 Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 86, 3635-3640. (Pubitemid 32755954)
63. Tsunoda T, Shibahara H, Hirano Y et al. 2003 Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecological Endocrinology 17, 281-286. (Pubitemid 37083033)
64. Ujioka T, Matsuura K, Tanaka N et al. 1998 Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. Human Reproduction 13, 3009-3015. (Pubitemid 28521841)
65. Ujioka T, Matsuura E, Kawano T et al. 1997 Role of progesterone in capillary permeability in hyperstimulated rats. Human Reproduction 12, 1629-1634. (Pubitemid 27406069)
66. Vajkoczy P, Menger MD, Vollmar B et al. 1999 Inhibition of tumor growth, angiogenesis, and microcirculation by the novel FIk-I inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1, 31-41.
67. Verheul HM, Hoekman K, Jorna AS et al. 2000 Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5, 45-50. (Pubitemid 30225457)
68. Villasante A, Pacheco A, Ruiz A et al. 2006 Vascular endothelial Cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. Journal of Clinical Endocrinology and Metabolism 92, 314-321.
69. Waltenberger J, Claesson-Welsh L, Siegbahn A et al. 1994 Different signal transduction properties of KDR and F1t1, two receptors for vascular endothelial growth factor. Journal of Biological Chemistry 269, 26988-26995. (Pubitemid 24332901)
70. Wang TH, Horng SG, Chang CL et al. 2002 Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. Journal of Clinical Endocrinology and Metabolism 87, 3300-3308. (Pubitemid 34816380)
71. Watkins RH, D'Angio CT, Ryan RM et al. 1999 Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. American Journal of Physiology 276, 858-867.
72. Wedge SR, Ogilvie DJ, Dukes M et al. 2000 ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Research 60, 970-975. (Pubitemid 30129533)
73. Wei MH, Popescu NC, Lerman MI et al. 1996 Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6pl2. Human Genetics 97, 794-797. (Pubitemid 26150850)
74. Whelan JG 3rd, Vlahos NF 2000 The ovarian hyperstimulation syndrome. Fertility and Sterility 73, 883-896.
75. Xu L, Yoneda J, Herrera C et al. 2000 Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology 16, 445-454.
76. Yamamoto S, Konishi I, Tsuruta E et al. 1997 Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecologic Endocrinology 11, 371-381. (Pubitemid 28029579)
77. Yan Z, Weich HA, Bernart W, Breckwoldt M et al. 1993 Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. Journal of Clinical Endocrinology and Metabolism 77, 1723-1725. (Pubitemid 24000942)
78. Yukita A, Asano M, Okamoto T et al. 2000 Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Research 20, 155-160. (Pubitemid 30189747)